Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 4789 is a member of the microRNA (miRNA) family, which comprises short (20–24 nucleotides) non-coding RNAs that regulate gene expression post-transcriptionally by influencing mRNA stability and translation in multicellular organisms[1][5]. Like other miRNAs, MIR4789 is transcribed as part of a primary transcript (pri-miRNA), processed into a precursor (pre-miRNA), and further processed by Dicer to produce a mature miRNA incorporated into the RNA-induced silencing complex (RISC)[1][5]. While the general biological roles of miRNAs include cell differentiation, proliferation, apoptosis, and immune regulation[4][8], no specific function, disease association, or pharmacological targeting has been reported for MIR4789 itself[1][5]. There is currently no detailed information on the specific function, disease relevance, or therapeutic targeting of MicroRNA 4789 in humans. Its nomenclature, genomic location, and classification as a miRNA are established, but no literature describes its unique biological or clinical significance[1][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 4789 (MIR4789).